000285740 001__ 285740
000285740 005__ 20260320151751.0
000285740 0247_ $$2doi$$a10.1016/j.parkreldis.2026.108265
000285740 0247_ $$2pmid$$apmid:41780490
000285740 0247_ $$2ISSN$$a1353-8020
000285740 0247_ $$2ISSN$$a1873-5126
000285740 037__ $$aDZNE-2026-00297
000285740 041__ $$aEnglish
000285740 082__ $$a610
000285740 1001_ $$aHasoon, Jahfer$$b0
000285740 245__ $$aMultimodal biomarkers to predict dementia-free survival and cognitive decline in mild cognitive impairment with Lewy bodies.
000285740 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2026
000285740 3367_ $$2DRIVER$$aarticle
000285740 3367_ $$2DataCite$$aOutput Types/Journal article
000285740 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1774016172_12449
000285740 3367_ $$2BibTeX$$aARTICLE
000285740 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285740 3367_ $$00$$2EndNote$$aJournal Article
000285740 520__ $$aPredicting conversion to dementia in mild cognitive impairment with Lewy bodies (MCI-LB) remains challenging. Furthermore, there is limited research combining predictive markers in MCI-LB. We explored the utility of Lewy body and Alzheimer's disease biomarkers for the prediction of future decline in MCI-LB.Eighty-seven participants were included (35 MCI-AD, 15 possible MCI-LB, 37 probable MCI-LB). Baseline assessment involved MRI, EEG, bloods and cognitive testing. Follow up was completed yearly with review of diagnosis and repeat cognitive testing. We evaluated the relationship between baseline biomarkers and dementia-free survival time. We also investigated biomarker effects on future cognitive decline using annualised change in ACE-R. The value of combining biomarkers with baseline cognitive test score was assessed using forward selection.In probable MCI-LB, shorter dementia-free survival time was strongly associated with smaller hippocampal volume (hazard ratio = 2.36, 95% CI 1.41 - 3.94) and smaller posterior cortical volume (hazard ratio = 2.62, 95% CI 1.35 - 5.10). Reduced EEG dominant frequency, increased relative delta and theta power, reduced insula volume, increased plasma tau, and increased plasma GFAP were also associated with an increased hazard ratio. Posterior atrophy, hippocampal atrophy, and GFAP were significant predictors of ACE-R decline. Combining blood and MRI biomarkers improved model quality for dementia-free survival (GFAP and hippocampal atrophy) and cognitive test decline (AB ratio and posterior atrophy).Blood, EEG and MRI biomarkers of dementia with Lewy bodies, neurodegeneration and Alzheimer's co-pathology demonstrate utility for prognosis in MCI-LB. Combining biomarkers across modalities improves prognostic accuracy.
000285740 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285740 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285740 650_7 $$2Other$$aDementia with lewy bodies
000285740 650_7 $$2Other$$aDisease progression
000285740 650_7 $$2Other$$aEEG
000285740 650_7 $$2Other$$aMRI
000285740 650_7 $$2Other$$aMild cognitive impairment
000285740 650_7 $$2Other$$aPlasma biomarkers
000285740 7001_ $$aHamilton, Calum A$$b1
000285740 7001_ $$aFirbank, Michael$$b2
000285740 7001_ $$0P:(DE-2719)9002248$$aSchumacher, Julia$$b3$$udzne
000285740 7001_ $$aColloby, Sean J$$b4
000285740 7001_ $$aDonaghy, Paul C$$b5
000285740 7001_ $$aTaylor, John-Paul$$b6
000285740 7001_ $$aThomas, Alan J$$b7
000285740 773__ $$0PERI:(DE-600)2027635-7$$a10.1016/j.parkreldis.2026.108265$$gVol. 145, p. 108265 -$$p108265$$tParkinsonism & related disorders$$v145$$x1353-8020$$y2026
000285740 8564_ $$uhttps://pub.dzne.de/record/285740/files/DZNE-2026-00297.pdf$$yRestricted
000285740 8564_ $$uhttps://pub.dzne.de/record/285740/files/DZNE-2026-00297.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285740 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9002248$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000285740 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285740 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bPARKINSONISM RELAT D : 2022$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-12
000285740 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-11-12
000285740 9201_ $$0I:(DE-2719)5000014$$kAG Storch$$lNon-Motor Symptoms in Parkinson's disease$$x0
000285740 980__ $$ajournal
000285740 980__ $$aEDITORS
000285740 980__ $$aVDBINPRINT
000285740 980__ $$aI:(DE-2719)5000014
000285740 980__ $$aUNRESTRICTED